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Abstract
Little is known regarding alterations of the renin-angiotensin system in patients referred for cardiac catheterization. Here, we
measured plasma levels of active renin and aldosterone in patients referred for cardiac catheterization in order to determine the
prevalence of elevated renin, aldosterone, and the aldosterone-renin ratio.
A chemiluminescence assay was used to measure plasma aldosterone concentration (PAC) and active renin levels in 833
consecutive patients, after an overnight fasting and without any medication for least 12hours. We evaluated associations of the
hormonal elevations in relation to hypertension, atrial ﬁbrillation (AF), hypertensive cardiomyopathy, coronary artery disease (CAD),
valvular disease, impaired left ventricular ejection fraction (LVEF<35%), and pulmonary hypertension (arterial pulmonary mean
pressure >25 mm Hg).
Hyperaldosteronism occurred in around one-third of all examined patients, without signiﬁcant differences between patients with or
without the named cardiac diseases. In a comparison between patients with or without any given cardiac disease condition, renin
was signiﬁcantly elevated in patients with either hypertension (36.4% vs 15.9%), CAD (33.9% vs 22.1%), or impaired LVEF (47.3% vs
24.8%). The angiotensin-renin ratio was elevated in AF patients and in patients with hypertensive cardiomyopathy. Patients with AF
and coexisting hypertension had elevated renin more frequently than AF patients without coexisting hypertension (35.3% vs 16.5%;
P= .005). Patients with persistent/permanent AF more frequently had elevated renin than patients with paroxysmal AF (34.1% vs
15.8%; P= .007).
This prospective study of consecutive cardiac disease patients referred for cardiac catheterization has revealed distinct cardiac
disease condition-associated differences in the frequencies of elevations in plasma renin, PAC, and the aldosterone-renin ratio.
Abbreviations: AF = atrial ﬁbrillation, ARR = aldosterone-renin ratio, AVS = adrenal vein sampling, CAD = coronary artery
disease, IQR = interquartile ranges, LV = left ventricular, LVEF = left ventricular ejection fraction, PAC = plasma aldosterone
concentration.
Keywords: aldosterone, aldosterone-renin ratio, atrial ﬁbrillation, coronary artery disease, pulmonary artery pressures, reduced
LVEF, rennin, valvular heart disease, venous plasma sampling
1. Introduction
Excess aldosterone secretion plays a key role in raising blood
pressure in many patients, and not only in those who have
primary aldosteronism, but also in a multitude of patients with
low-renin primary (formerly termed “essential”) hypertension
and those with hypertension associated with overweight
obesity.[1] In many such patients, current imaging techniques
fail to allow identiﬁcation of adrenocortical pathologies and only
adrenal vein sampling (AVS) permits identiﬁcation of lateralized
aldosterone excess.[2–4] More recently an elevation in aldosterone
levels was also reported in hypertensive patients with atrial
ﬁbrillation (AF).[5–7] However, whether aldosterone is elevated in
normotensive patients with AF or other cardiac conditions is
unknown. Furthermore, it is unclear whether alterations of the
aldosterone-renin ratio (ARR) exist in unselected cardiac patients
undergoing cardiac catheterization.
The present study undertook to prospectively measure plasma
renin and aldosterone concentrations and the ARR in unselected
patients undergoing cardiac catheterization with the intent of
addressing the following questions: (i) Is there an elevation in
aldosterone in various cardiac diseases/conditions? (ii) Can we
reproduce, in this special patient population, the previously
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reported ﬁndings of aldosterone elevation in hypertension? (iii) Is
AF a state of aldosterone elevation due to hypertension or is it
independent of hypertension?
We measured aldosterone and active renin levels in a large
cohort of patients and evaluated the associations of hormonal
elevations in relation to speciﬁc and different cardiac diseases.
2. Patients and methods
The study was approved by the ethical committee of the Lucerne
(Study Number 12032) and was conducted in compliance with
the Declaration of Helsinki. All subjects provided written
informed consent.
We studied patients in whom left heart catheterization did not
yield a clear explanation for their symptoms and their heart
disease could not be unambiguously established noninvasively.
The patients underwent a right heart catheterization after
overnight fasting and without any medication for least 12 to
24hours. Blood was withdrawn on the venous side from patients
in the supine position. Catheterization and blood withdrawal
procedures were never performed during the week-end or in the
emergency unit.
Blood sampling for plasma aldosterone concentration (PAC)
and renin was taken from the renal vein during catheterization.
Catheters used included a Judkins right heart catheter, a
multipurpose catheter, or an Amplatz III catheter. Blood samples
(4mL) were drawn into EDTA vacutainer tubes, processed for
preparation of cell-free plasma in the central laboratory of the
hospital. Plasma samples were sent to Viollier AG (Allschwil,
Switzerland) for analysis of renin and aldosterone.
Aldosterone and renin measurements were performed using
validated LIAISONAldosterone and LIAISON direct active renin
concentration (DRC) commercial (DiaSorin) assay kits (Diasorin
Switzerland AG, Rotkreuz, Switzerland). Measurements were
performed on a LIAISON XL Analyzer.[7] Inter-assay and intra-
assay coefﬁcients of variability (CV) for renin determination are
between 2.1–2.4% and 6.8–7.3%, respectively. Inter-assay CV
and intra-assay CV for aldosterone determination are between
1.8–3.5% and 5.6–9.5% respectively. The elevation of renin was
deﬁned as a level > 33.5 mU/L and that of aldosterone as > 0.45
nmol/L. The elevation of aldosterone–renin ratio (ARR) was
considered if it was > 0.14nmol/L/mU/L.
Cardiac disease characterization was made after right heart
catheterization. Hypertension was deﬁned if blood pressure was
above 150/90 mm Hg and it was recorded in medical history or
the patient was treated for it. In the absence of ARR elevation or
dynamically relevant renal arterial stenosis, the hypertension was
attributed to primary (formerly called essential) hypertension.
Hypertensive cardiomyopathy was deﬁned if hypertension was
present during catherization and coronary arteries were
thickened and stenosis of the renal arteries was observed. AF
was diagnosed if present at the time of catheter investigation or if
an AF episode of at least 2 minutes duration was detected by 7-
day continuous Holter ECG monitoring. Valvular heart disease
was named moderate or severe according to the need of valvular
replacement. Coronary artery disease (CAD) was established if
there was coronary stenosis of 50%ormore in at least 1 coronary
vessel. Patients had either sinus rhythm or permanent or
paroxysmal AF. Pulmonary hypertension was established if
mean pulmonary artery pressure was> 25 mmHg. Hypertensive
cardiomyopathy was established if there was LV hypertrophy
and there were signs of hypertension, inclusion of coronary artery
disease, or any other conditions that might explain symptoms
which were not answerable after left heart catheterization.
Valvular heart disease was established if one of the heart valves
was regurgitated or stenotic.
2.1. Statistical analysis
The analysis included all patients, and the patients were grouped
according to the following cardiac diseases: hypertension, AF,
pulmonary hypertension, hypertensive cardiomyopathy, CAD,
valvular disease, LVEF below 35%. The results are presented as
percentages for categorical variables and analyzed using the
Pearson chi-square test or Fisher’s exact test as appropriate.
Continuous variables are expressed as median and interquartile
ranges (IQR) and analyzed using the Mann-Whitney U test.
P< .05 was taken as level of statistical signiﬁcance. IBM SPSS
Statistics version 22 (IBM Corp., Armonk, NY) was used for
statistical analyses.
3. Results
A total of 833 patients underwent left heart catheterization due to
different cardiac diseases between February 2009 and March
2015. The most frequent diagnoses were hypertension (56.2%)
and CAD (45%), followed by AF (20.4%), valvular heart disease
(17.8%), and hypertensive cardiomyopathy (7.1%). Many
patients had more than 1 diagnosis. The left ventricular ejection
fraction (LVEF) was below 35% in 45 of 796 catheterized
patients (in 37 of the 833 LVEF could not be calculated). The
mean pulmonary artery pressure was above 25 mm Hg in 237
patients.
Figure 1 presents a numerical ﬂow chart of the patient grouped
according to speciﬁc cardiac disease conditions.
Aldosterone values were available for all patients (n=833).
Aldosterone was elevated in 272 patients (32.7%) with a median
value of 0.82nmol/L (IQR 0.59 – 1.31nmol/L). Renin values
were available for 826 patients. Renin was elevated in 228
patients (27.4%) with a median value of 77.95mU/L (IQR
47.4–150.4mU/L). The percentages of patients with elevated
aldosterone, renin, and ARR are given in Table 1.
Hyperaldosteronism occurred in around one-third of all
examined patients, without signiﬁcant differences between
patients with or without the named cardiac diseases. Trends
only were noted in patients with impaired LVEF (P= .074)
(Table 1).
Renin was signiﬁcantly elevated in patients with hyperten-
sion, with CAD, and in patients with impaired LVEF (Table 1).
Renin levels were on average 2-fold higher in hypertensive
patients than in patients without hypertension (21.3mU/L IQR
9.6, 53.3mU/L vs 11.6 IQR 7.0, 20.9mU/L; P< .001). Patients
with CAD had also higher renin levels than patients without
CAD (20.1mU/L, IQR 10.5, 47.2mU/L vs 11.8mU/L IQR 6.6,
30.1mU/L; P< .001). Patients with impaired LVEF had higher
renin levels than patients with normal LVEF of 26.4mU/L (IQR
10.4, 129.4mU/L) versus 14.0mU/L (IQR 7.0, 33.5; mU/L;
P< .001).
ARR was signiﬁcantly elevated in patients with AF (P= .034)
and hypertensive cardiomyopathy (P= .005) compared to the
patients without AF and hypertensive cardiomyopathy, respec-
tively (Table 1).
Patients with AF and coexisting hypertension had a 2-fold
higher prevalence of elevated renin than AF patients without
coexisting hypertension (35.3% vs 16.5%; P= .005). Aldoste-
rone elevation was not different between these patient groups
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(35.3% vs 40.0%; P= .53). Additionally, more patients with
persistent or permanent AF had elevated renin levels than patients
with paroxysmal AF (34.1% vs 15.8%; P= .007). Aldosterone
elevation was also not different between these 2 patient groups
(36.4% vs 41.3%; P= .52).
4. Discussion
To the best of our knowledge this is the ﬁrst prospective study to
have measured plasma aldosterone and active renin concen-
trations in a relatively large population of patients submitted to
cardiac catheterization. In such patients, and particularly in those
with severe LV dysfunction, liver synthesis of angiotensinogen
can be limited, thus biasing the assessment of renin by means of
plasma renin activity, the most widely used renin assay of the past
decades. Of note, the direct sandwich assay of active renin
concentration (LIAISON DRC) renders the assessment of plasma
active renin totally independent of renin substrate availability
and therefore provides a far more accurate measurement of renin
in these types of patients.
Not unexpectedly, considering that renin is a potent pressor
hormone, we found that the proportion of patients with elevated
plasma active renin was higher among the patients with arterial
hypertension. Moreover, it was higher also among those with
CAD and with impaired LV ejection fraction, which is consistent
with the notion that activation of the renin-angiotensin-
aldosterone-system (RAAS) accelerates atherogenesis and that
severe LV systolic dysfunction implies an activation of the RAAS
because of under ﬁlling.[8]
A further important ﬁnding of this study concerns the
observation that the ARR was elevated in the patients with AF
and hypertensive cardiomyopathy. This occurred because PAC
was elevated more than active renin. Although the elevation of
PAC did not achieve statistical signiﬁcance, the ﬁnding indicates
the ARR provides a better assessment of the volume status and
thus of atrial stretch. Notably, an elevation in aldosterone
occurred in around one-third of all the examined patients with
cardiac diseases. Patients with either valvular heart disease or
elevated pulmonary arterial pressures did not show any differ-
ences regarding the presence of hyperaldosteronism or hyper-
renism compared to patients without such conditions. These
ﬁndings prompt a recommendation for the clinical practice to
consider and search for the presence of hyperaldosteronism in
patients with hypertensive heart disease and atrial ﬁbrillation, but
not in patients with CAD or valvular heart disease and elevated
pulmonary artery pressure.
The high prevalence of hyperrenism and hyperaldosteronism in
the patients with hypertension and with hypertensive cardiomy-
opathy causing AF is an important novel ﬁnding, in as much as
Table 1
Percentages of patients with elevated aldosterone, renin, or
aldosterone-renin ratio: comparisons between patients without
and with named cardiac diseases: analysis of all included patients.
Hypertension No Yes P
PAC elevated, % 128/364 (35.2) 144/467 (30.8) .19
Renin elevated, % 58/364 (15.9) 170/467 (36.4) <.001
ARR elevated, % 15/351 (4.3) 12/467 (2.6) .18
Hypertensive cardiomyopathy No Yes P
PAC elevated, % 201/593 (33.9) 12/45 (26.7) .32
Renin elevated, % 178/593 (30.0) 13/45 (28.9) .87
ARR elevated, % 13/584 (2.2) 4/42 (9.5) .005
Atrial ﬁbrillation No Yes P
PAC elevated, % 208/663 (31.4) 64/170 (3726) .12
Renin elevated, % 184/663 (27.8) 44/170 (25.9) .63
ARR elevated, % 17/650 (2.6) 10/170 (5.9) .034
Coronary artery disease No Yes P
PAC elevated, % 140/458 (30.6) 132/375 (35.2) .16
Renin elevated, % 101/458 (22.1) 127/375 (33.9) <.001
ARR elevated, % 20/447 (4.5) 7/373 (1.9) .038
Valvular heart disease No Yes P
PAC elevated, % 223/685 (32.6) 49/148 (33.1) .90
Renin elevated, % 179/685 (26.1) 49/148 (33.1) .084
ARR elevated, % 24/676 (3.6) 3/144 (2.1) .37
Left ventricular ejection fraction <35% No Yes P
PAC elevated, % 221/705 (31.3) 37/91 (40.4) .074
Renin elevated, % 175/705 (24.8) 43/91 (47.3) <.001
ARR elevated, % 21/696 (3.0) 2/91 (2.2) .66
Pulmonary hypertension (atrial
pulmonary mean pressure >25 mm Hg
No Yes P
PAC elevated, % 125/402 (31.1) 75/237 (31.6) .86
Renin elevated, % 108/402 (26.9) 68/237 (28.7) .62
ARR elevated, % 8/397 (2.0) 9/231 (3.9) .16
ARR= angiotensin-renin ratio, PAC=plasma aldosteron concentration.
To
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Figure 1. Numerical ﬂow chart of patient grouping according to the cardiac
disease condition.
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excess PAC in the setting of a high sodium intake has been
associated with cardiac inﬂammation, scars, and myocardial
remodeling, all changes that can create the stage for re-entry
mechanisms and thus AF.[9–11] The ﬁnding is consistent with
results from investigations on patients with primary aldosteronism
in whom a high frequency of AFwas found using retrospective [12]
and prospective [13] study designs. Furthermore, it is also in
accordancewith the report of a relationship of excess PACwithLV
hypertrophy, regardless of the elevation of blood pressure.[14]
4.1. Limitations of the study
There are several limitations to be acknowledged in this study.
We could not ascertain what proportion of the hypertensive
patients with elevated ARR had primary aldosteronism. This is
because after having gone cardiac catheterization, they were
referred back to their attending physician, and therefore not
submitted to the necessary follow-up. Although much care was
taken to obtain right and left adrenal venin blood we could not
establish selectivity of the AVS, and therefore could not calculate
the lateralization index and establish lateralized PAC excess.
Lastly, some of the patients could not be studied after withdrawal
of the drugs affecting the RAAS and the ARR. However, our
results remained essentially unchanged after a sensitivity analysis
that excluded the patients on beta blockers, the drugs that most
affect the ARR.
5. Conclusions
In summary, this large prospective study of consecutive cardiac
disease patients referred for cardiac catheterization has docu-
mented distinct differences with regard to the presence of
elevations in plasma renin, PAC, and the ARR. The patients with
arterial hypertension, CAD, and severe LV systolic atrophic
dysfunction had a higher rate of hyperreninism. The higher
proportion of hypertensive patients with hyperrenism, in
particular those who also had AF, suggests that several cases
of primary aldosteronism were likely concealed in these groups.
Overall, our ﬁndings are consistent with the contention that
regardless of renin, aldosterone excess adversely affects LVH and
atrial remodeling thereby setting the pathological stage for
arrhythmia, including atrial and possibly ventricular ﬁbrillation.
This could explain, at least in part, the reported reductions in
death, including sudden death, in large clinical trials using
mineralocorticoid receptor antagonists.[15,16]
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